This profile hasn't yet passed our validation checks
Submit your email to push it up the queue
Baxalta Us Inc.
Baxalta US Inc., a prominent biopharmaceutical company, is headquartered in the United States and operates extensively across North America and Europe. Founded in 2015, Baxalta emerged from a spin-off of Baxter International, focusing on innovative therapies for rare diseases and complex conditions. The company is renowned for its expertise in haematology, immunology, and oncology, offering a range of unique products that address unmet medical needs. Baxalta's core offerings include advanced biologics and specialty pharmaceuticals, distinguished by their commitment to patient-centric solutions and cutting-edge research. With a strong market position, Baxalta has achieved notable milestones, including significant advancements in treatment options for bleeding disorders. The company continues to be a leader in the biopharmaceutical industry, dedicated to improving patient outcomes through innovation and excellence.
DitchCarbon Score
How does Baxalta Us Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Baxalta Us Inc.'s score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Baxalta US Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of available figures. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and initiatives. Baxalta's climate strategy is aligned with the broader goals set by its parent company, Takeda. While no specific reduction targets or achievements are listed for Baxalta, it is important to note that emissions data and climate initiatives may be cascaded from Takeda, which operates under established frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). As a subsidiary, Baxalta's climate commitments are likely informed by Takeda's overarching sustainability goals, which include significant efforts to reduce carbon emissions across all scopes. However, without specific data or targets from Baxalta itself, the details of its individual climate commitments remain unclear. In summary, while Baxalta US Inc. does not provide specific emissions data or reduction targets, it is positioned within a corporate structure that prioritises climate action through its parent company, Takeda Pharmaceutical Company Limited.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Baxalta Us Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
